VRCA Verrica Pharmaceuticals Inc
Price (delayed)
$0.4587
Market cap
$42.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.48
Enterprise value
$41.71M
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and
Highlights
The EPS is up by 20% since the previous quarter
VRCA's debt is down by 2.5% QoQ
The equity has dropped by 150% year-on-year but it has surged by 71% since the previous quarter
The quick ratio has plunged by 63% YoY but it has increased by 45% from the previous quarter
The gross margin has decreased by 25% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of VRCA
Market
Valuations
Earnings
Shares outstanding
91.78M
Market cap
$42.1M
Enterprise value
$41.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.51
Revenue
$7.57M
Gross profit
$4.83M
Operating income
-$65.92M
Net income
-$76.58M
EBIT
-$67.17M
EBITDA
-$65.9M
Free cash flow
-$60.95M
Per share
Balance sheet
Liquidity
EPS
-$1.48
EPS diluted
-$1.48
Free cash flow per share
-$1.18
Book value per share
-$0.22
Revenue per share
$0.15
TBVPS
$1.04
Total assets
$54.13M
Total liabilities
$63.99M
Debt
$45.94M
Equity
-$9.86M
Working capital
$22.17M
Debt to equity
-4.66
Current ratio
1.76
Quick ratio
1.6
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
-871%
Gross margin
63.8%
Net margin
-1,012.1%
Operating margin
-871.3%
Return on assets
-149.1%
Return on equity
N/A
Return on invested capital
-177.3%
Return on capital employed
-267.4%
Return on sales
-887.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRCA stock price
How has the Verrica Pharmaceuticals stock price performed over time
Intraday
-1.99%
1 week
-4.28%
1 month
-17.8%
1 year
-93.3%
YTD
-34.47%
QTD
3.73%
Financial performance
How have Verrica Pharmaceuticals's revenue and profit performed over time
Revenue
$7.57M
Gross profit
$4.83M
Operating income
-$65.92M
Net income
-$76.58M
Gross margin
63.8%
Net margin
-1,012.1%
The revenue rose by 48% year-on-year but it has declined by 18% since the previous quarter
Verrica Pharmaceuticals's operating margin has increased by 32% YoY but it has decreased by 3.3% from the previous quarter
Verrica Pharmaceuticals's gross profit has decreased by 29% from the previous quarter but it has increased by 10% YoY
The gross margin has decreased by 25% YoY and by 14% from the previous quarter
Growth
What is Verrica Pharmaceuticals's growth rate over time
Valuation
What is Verrica Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.51
The EPS is up by 20% since the previous quarter
The equity has dropped by 150% year-on-year but it has surged by 71% since the previous quarter
The stock's price to sales (P/S) is 95% less than its 5-year quarterly average of 61.4 and 81% less than its last 4 quarters average of 16.9
The revenue rose by 48% year-on-year but it has declined by 18% since the previous quarter
Efficiency
How efficient is Verrica Pharmaceuticals business performance
The return on assets has dropped by 72% year-on-year and by 2.1% since the previous quarter
The return on invested capital has increased by 32% year-on-year
The ROS is up by 28% year-on-year but it is down by 8% since the previous quarter
Dividends
What is VRCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRCA.
Financial health
How did Verrica Pharmaceuticals financials performed over time
Verrica Pharmaceuticals's total assets is 15% lower than its total liabilities
Verrica Pharmaceuticals's total assets has surged by 64% QoQ but it has decreased by 34% YoY
The quick ratio has plunged by 63% YoY but it has increased by 45% from the previous quarter
The equity has dropped by 150% year-on-year but it has surged by 71% since the previous quarter
VRCA's debt is down by 2.5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.